• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

登革病毒NS3特异性、HLA-DR15限制性细胞毒性CD4+ T细胞克隆识别中涉及的氨基酸鉴定。

Identification of amino acids involved in recognition by dengue virus NS3-specific, HLA-DR15-restricted cytotoxic CD4+ T-cell clones.

作者信息

Zeng L, Kurane I, Okamoto Y, Ennis F A, Brinton M A

机构信息

Department of Biology, Georgia State University, Atlanta 30303, USA.

出版信息

J Virol. 1996 May;70(5):3108-17. doi: 10.1128/JVI.70.5.3108-3117.1996.

DOI:10.1128/JVI.70.5.3108-3117.1996
PMID:8627790
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC190173/
Abstract

The majority of T-cell clones derived from a donor who experienced dengue illness following receipt of a live experimental dengue virus type 3 (DEN3) vaccine cross-reacted with all four serotypes of dengue virus, but some were serotype specific or only partially cross-reactive. The nonstructural protein, NS3, was immuno-dominant in the CD4+ T-cell response of this donor. The epitopes of four NS3-specific T-cell clones were analyzed. JK15 and JK13 recognized only DEN3 NS3, while JK44 recognized DEN1, DEN2, and DEN3 NS3 and JK5 recognized DEN1, DEN3, and West Nile virus NS3. The epitopes recognized by these clones on the DEN3 NS3 protein were localized with recombinant vaccinia viruses expressing truncated regions of the NS3 gene, and then the minimal recognition sequence was mapped with synthetic peptides. Amino acids critical for T-cell recognition were assessed by using peptides with amino acid substitutions. One of the serotype-specific clones (JK13) and the subcomplex- and flavivirus-cross-reactive clone (JK5) recognized the same core epitope, WITDFVGKTVW. The amino acid at the sixth position of this epitope is critical for recognition by both clones. Sequence analysis of the T-cell receptors of these two clones showed that they utilize different VP chains. The core epitopes for the four HLA-DR15-restricted CD4+ CTL clones studied do not contain motifs similar to those proposed by previous studies on endogenous peptides eluted from HLA-DR15 molecules. However, the majority of these dengue virus NS3 core epitopes have a positive amino acid (K or R) at position 8 or 9. Our results indicate that a single epitope can induce T cells with different virus specificities despite the restriction of these T cells by the same HLA-DR15 allele. This finding suggests a previously unappreciated level of complexity for interactions between human T-cell receptors and viral epitopes with very similar sequences on infected cells.

摘要

大多数源自一名在接种活的实验性3型登革病毒(DEN3)疫苗后感染登革热的供体的T细胞克隆与登革病毒的所有四种血清型发生交叉反应,但有些是血清型特异性的或仅部分交叉反应。非结构蛋白NS3在该供体的CD4+ T细胞应答中具有免疫优势。分析了四个NS3特异性T细胞克隆的表位。JK15和JK13仅识别DEN3 NS3,而JK44识别DEN1、DEN2和DEN3 NS3,JK5识别DEN1、DEN3和西尼罗河病毒NS3。利用表达NS3基因截短区域的重组痘苗病毒对这些克隆在DEN3 NS3蛋白上识别的表位进行定位,然后用合成肽绘制最小识别序列。通过使用具有氨基酸取代的肽评估对T细胞识别至关重要的氨基酸。其中一个血清型特异性克隆(JK13)和亚复合物及黄病毒交叉反应克隆(JK5)识别相同的核心表位WITDFVGKTVW。该表位第六位的氨基酸对两个克隆的识别至关重要。对这两个克隆的T细胞受体进行序列分析表明,它们利用不同的Vβ链。所研究的四个HLA-DR15限制性CD4+ CTL克隆的核心表位不包含与先前关于从HLA-DR15分子洗脱的内源性肽的研究所提出的基序相似的基序。然而,这些登革病毒NS3核心表位中的大多数在第8或9位具有正氨基酸(K或R)。我们的结果表明,尽管这些T细胞受相同的HLA-DR15等位基因限制,但单个表位可诱导具有不同病毒特异性的T细胞。这一发现提示了人类T细胞受体与感染细胞上序列非常相似的病毒表位之间相互作用的复杂性,而这种复杂性此前未被充分认识。

相似文献

1
Identification of amino acids involved in recognition by dengue virus NS3-specific, HLA-DR15-restricted cytotoxic CD4+ T-cell clones.登革病毒NS3特异性、HLA-DR15限制性细胞毒性CD4+ T细胞克隆识别中涉及的氨基酸鉴定。
J Virol. 1996 May;70(5):3108-17. doi: 10.1128/JVI.70.5.3108-3117.1996.
2
Definition of the region on NS3 which contains multiple epitopes recognized by dengue virus serotype-cross-reactive and flavivirus-cross-reactive, HLA-DPw2-restricted CD4+ T cell clones.NS3上包含多个表位的区域的定义,这些表位可被登革病毒血清型交叉反应性和黄病毒交叉反应性、HLA-DPw2限制性CD4+ T细胞克隆识别。
J Gen Virol. 1998 Apr;79 ( Pt 4):697-704. doi: 10.1099/0022-1317-79-4-697.
3
A single nine-amino acid peptide induces virus-specific, CD8+ human cytotoxic T lymphocyte clones of heterogeneous serotype specificities.一种单一的九氨基酸肽可诱导出具有不同血清型特异性的病毒特异性CD8⁺人细胞毒性T淋巴细胞克隆。
J Exp Med. 1995 Sep 1;182(3):853-63. doi: 10.1084/jem.182.3.853.
4
Dengue virus-specific, human CD4+ CD8- cytotoxic T-cell clones: multiple patterns of virus cross-reactivity recognized by NS3-specific T-cell clones.登革病毒特异性人类CD4+ CD8-细胞毒性T细胞克隆:NS3特异性T细胞克隆识别的多种病毒交叉反应模式
J Virol. 1991 Apr;65(4):1823-8. doi: 10.1128/JVI.65.4.1823-1828.1991.
5
Flavivirus-cross-reactive, HLA-DR15-restricted epitope on NS3 recognized by human CD4+ CD8- cytotoxic T lymphocyte clones.人CD4+ CD8-细胞毒性T淋巴细胞克隆识别的黄病毒交叉反应性、HLA-DR15限制性NS3表位。
J Gen Virol. 1995 Sep;76 ( Pt 9):2243-9. doi: 10.1099/0022-1317-76-9-2243.
6
Dengue virus-specific, HLA-B35-restricted, human CD8+ cytotoxic T lymphocyte (CTL) clones. Recognition of NS3 amino acids 500 to 508 by CTL clones of two different serotype specificities.登革病毒特异性、HLA - B35限制的人类CD8 + 细胞毒性T淋巴细胞(CTL)克隆。两种不同血清型特异性的CTL克隆对NS3氨基酸500至508的识别。
J Immunol. 1995 Feb 1;154(3):1287-95.
7
Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotype-specific and a panel of serotype-cross-reactive human CD4+ cytotoxic T-lymphocyte clones.登革4型病毒衣壳蛋白上两个表位的鉴定,这两个表位可被血清型特异性及一组血清型交叉反应性人类CD4+细胞毒性T淋巴细胞克隆识别。
J Virol. 1996 Jan;70(1):141-7. doi: 10.1128/JVI.70.1.141-147.1996.
8
Definition of an epitope on NS3 recognized by human CD4+ cytotoxic T lymphocyte clones cross-reactive for dengue virus types 2, 3, and 4.对登革病毒2型、3型和4型具有交叉反应性的人CD4+细胞毒性T淋巴细胞克隆所识别的NS3上一个表位的定义。
Virology. 1998 Jan 20;240(2):169-74. doi: 10.1006/viro.1997.8925.
9
Analysis of murine CD8(+) T-cell clones specific for the Dengue virus NS3 protein: flavivirus cross-reactivity and influence of infecting serotype.针对登革病毒NS3蛋白的小鼠CD8(+) T细胞克隆分析:黄病毒交叉反应性及感染血清型的影响
J Virol. 1999 Jan;73(1):398-403. doi: 10.1128/JVI.73.1.398-403.1999.
10
Recognition of dengue virus NS1-NS2a proteins by human CD4+ cytotoxic T lymphocyte clones.人CD4+细胞毒性T淋巴细胞克隆对登革病毒NS1-NS2a蛋白的识别。
Virology. 1997 Aug 4;234(2):383-6. doi: 10.1006/viro.1997.8648.

引用本文的文献

1
Lesional senescent CD4 T cells mediate bystander cytolysis and contribute to the skin pathology of human cutaneous leishmaniasis.病变衰老的 CD4 T 细胞介导旁观者细胞溶解,并导致人类皮肤利什曼病的皮肤病理学变化。
Front Immunol. 2024 Oct 21;15:1475146. doi: 10.3389/fimmu.2024.1475146. eCollection 2024.
2
Regional Variation of the CD4 and CD8 T Cell Epitopes Conserved in Circulating Dengue Viruses and Shared with Potential Vaccine Candidates.循环登革热病毒中和表位和潜在候选疫苗的 CD4 和 CD8 T 细胞表位的区域差异。
Viruses. 2024 May 5;16(5):730. doi: 10.3390/v16050730.
3
Genome tuning through HLA and KIR gene clusters impact susceptibility to dengue.通过HLA和KIR基因簇进行基因组调控会影响登革热易感性。
Infect Med (Beijing). 2023 May 11;2(3):167-177. doi: 10.1016/j.imj.2023.05.001. eCollection 2023 Sep.
4
Senescent T cells: Beneficial and detrimental roles.衰老的 T 细胞:有益和有害的作用。
Immunol Rev. 2023 Jul;316(1):160-175. doi: 10.1111/imr.13206. Epub 2023 Apr 25.
5
Low Activation of CD8 T Cells in response to Viral Peptides in Mexican Patients with Severe Dengue.墨西哥重症登革热患者对病毒肽的 CD8 T 细胞低反应性。
J Immunol Res. 2022 Mar 25;2022:9967594. doi: 10.1155/2022/9967594. eCollection 2022.
6
Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?登革病毒的适应性免疫:合理疫苗设计的滑坡还是坚实基础?
Pathogens. 2020 Jun 15;9(6):470. doi: 10.3390/pathogens9060470.
7
Human T Cell Response to Dengue Virus Infection.人类对登革热病毒感染的 T 细胞反应。
Front Immunol. 2019 Sep 4;10:2125. doi: 10.3389/fimmu.2019.02125. eCollection 2019.
8
Immune Responses to Dengue and Zika Viruses-Guidance for T Cell Vaccine Development.登革热和 Zika 病毒的免疫反应——T 细胞疫苗开发指南。
Int J Environ Res Public Health. 2018 Feb 23;15(2):385. doi: 10.3390/ijerph15020385.
9
Mapping HLA-A2, -A3 and -B7 supertype-restricted T-cell epitopes in the ebolavirus proteome.在埃博拉病毒蛋白组中绘制 HLA-A2、-A3 和 -B7 超型限制性 T 细胞表位。
BMC Genomics. 2018 Jan 19;19(Suppl 1):42. doi: 10.1186/s12864-017-4328-8.
10
Development of Peptide Vaccines in Dengue.登革热肽疫苗的研制。
Curr Pharm Des. 2018;24(11):1157-1173. doi: 10.2174/1381612823666170913163904.

本文引用的文献

1
Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles.与HLA - DR等位基因结合的天然加工肽之间的特异性和混杂性。
J Exp Med. 1993 Jul 1;178(1):27-47. doi: 10.1084/jem.178.1.27.
2
Analysis of mutant HLA-A2 molecules. Differential effects on peptide binding and CTL recognition.
J Immunol. 1994 Feb 1;152(3):1213-21.
3
Naturally processed cytokine-derived peptide bound to HLA-class II molecules.与II类组织相容性复合体分子结合的天然加工的细胞因子衍生肽。
J Immunol. 1993 Dec 1;151(11):5975-83.
4
Dengue: the risk to developed and developing countries.登革热:对发达国家和发展中国家的风险。
Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2395-400. doi: 10.1073/pnas.91.7.2395.
5
Nomenclature for factors of the HLA system, 1994.
Hum Immunol. 1994 Sep;41(1):1-20. doi: 10.1016/0198-8859(94)90077-9.
6
Definition of an HLA-DPw2-restricted epitope on NS3, recognized by a dengue virus serotype-cross-reactive human CD4+ CD8- cytotoxic T-cell clone.登革病毒血清型交叉反应性人类CD4+ CD8-细胞毒性T细胞克隆所识别的NS3上HLA-DPw2限制性表位的定义。
J Virol. 1993 Oct;67(10):6285-8. doi: 10.1128/JVI.67.10.6285-6288.1993.
7
A single nine-amino acid peptide induces virus-specific, CD8+ human cytotoxic T lymphocyte clones of heterogeneous serotype specificities.一种单一的九氨基酸肽可诱导出具有不同血清型特异性的病毒特异性CD8⁺人细胞毒性T淋巴细胞克隆。
J Exp Med. 1995 Sep 1;182(3):853-63. doi: 10.1084/jem.182.3.853.
8
Dengue virus-specific, HLA-B35-restricted, human CD8+ cytotoxic T lymphocyte (CTL) clones. Recognition of NS3 amino acids 500 to 508 by CTL clones of two different serotype specificities.登革病毒特异性、HLA - B35限制的人类CD8 + 细胞毒性T淋巴细胞(CTL)克隆。两种不同血清型特异性的CTL克隆对NS3氨基酸500至508的识别。
J Immunol. 1995 Feb 1;154(3):1287-95.
9
Genetic variation among dengue 2 viruses of different geographic origin.不同地理来源的登革2型病毒之间的基因变异。
Virology. 1983 Jul 30;128(2):271-84. doi: 10.1016/0042-6822(83)90255-6.
10
General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.表达外源基因的感染性痘苗病毒重组体的生产和选择通用方法。
J Virol. 1984 Mar;49(3):857-64. doi: 10.1128/JVI.49.3.857-864.1984.